

**SEVENTH EDITION NOW AVAILABLE!**

# The Precision Oncology Annual Trend Report

## Perspectives From Oncologists, Pathologists, and Payers

As part of the ongoing Novartis commitment, **The Precision Oncology Annual Trend Report: Perspectives From Oncologists, Pathologists, and Payers, Seventh Edition**, offers insights into the trending topics and discoveries taking place in the evolving field of precision oncology.




This year's report identifies notable differences in biomarker testing approaches between Medicare Advantage and commercial insurance plans.

### Did you know?

- In 2020, **83% of oncologists** used **PIK3CA biomarker testing** in breast cancer, and **81%** of payers surveyed\* covered it
- **94%** of oncologists used **BRAF V600 E/K biomarker testing** in melanoma, and **90%** of payers surveyed covered it
- Oncologist utilization of testing for the following mutations has significantly increased in 2020 (% utilization, % increase; at 95% confidence): **HER2 in NSCLC (76%, +73%), RET in NSCLC (80%, +40%), FGFR in bladder cancer (85%, +33%), and NTRK fusion (89%, +39%)**
- **24%** of oncologists and **25%** of payers report that **laboratory benefit managers (LBMs)** are highly influential in support of utilization and/or coverage decisions for oncology biomarker tests

## Highlights

**Oncologists, pathologists, and payers were most interested in learning more about these topic areas†:**



N=50 oncologists, 30 pathologists, 60 payers.

Q9C. Please indicate by tumor type the areas of precision oncology that you are most interested in learning about. Check all that apply.


NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

\*The 2020 survey included 50 oncologists, 30 pathologists, and 60 payers.

†Topic areas included represent the top 4 topics ranked by oncologists surveyed.

## Highlights (continued)

### 40% of oncologists strongly agree evidence supports incorporating ctDNA NGS “liquid biopsy” tests into clinical practice; fewer pathologists and payers disagree




N=50 oncologists, 25 pathologists, 30 payers.

Values in parentheses indicate percent change from 2019.

Q34. With regard to next-generation sequencing (NGS) technology and genomic sequencing panels (GSPs), please indicate whether you agree or disagree with the following statements on a scale from 1-7.

### The time required and obtaining sufficient tumor biopsy may be issues for NGS/GSP testing



N=50 oncologists, 25 pathologists.

Values in parentheses indicate percent change from 2019.

Q34. With regard to next-generation sequencing (NGS) technology and genomic sequencing panels (GSPs), please indicate whether you agree or disagree with the following statements on a scale from 1-7.

**The Precision Oncology Annual Trend Report** continues to bring to light developing trends and how they impact the important decisions being made to adopt and utilize precision oncology.

For a copy of *The Precision Oncology Annual Trend Report*,  
**contact your Novartis representative**  
 or visit [hcp.novartis.com/care-management](http://hcp.novartis.com/care-management).



ctDNA, circulating tumor DNA; GSP, genomic sequencing panel.

Reference: Novartis Oncology. *The Precision Oncology Annual Trend Report: Perspectives From Oncologists, Pathologists, and Payers*. 7th ed; 2021.

